About Us

Text size
view with small font size
view with medium font size
view with large font size

Overview

Our dedicated team is working each day to advance biomedical research and technologies directed towards the development of novel therapeutics, including monoclonal antibody and small molecule therapeutics.

Kyowa Kirin Pharmaceutical Research (KKR) contributes to the development of first-in-class therapeutics through application of Kyowa Hakko Kirin's (KHK) proprietary antibody technologies including Fully Human Antibody Discovery Technology, POTELLIGENT®, COMPLEGENT® and AccretaMab® platforms. KKR also discovers novel drugs, identified drug targets and is constantly improving our platform technologies.

Since its inception, KKR has focused on Open Innovation through several industry–academia collaborative programs. KKR was established in 1988 (as Gemini Science) and has supported the research of the La Jolla Institute for Immunology (LJI) for more than 25 years, creating an enduring and successful industry-academic collaboration. The collaborative efforts between KKR and LJI have led to the development of several promising drug discovery and development programs, including multiple clinical stage therapeutic programs. KKR also works with researchers from several other leading academic institutions and industry partners to enhance its network-based drug discovery activities.

For more information on KHK's R&D activities, please visit Kyowa Hakko Kirin Global Site.

To Page Top